BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grau C, Baumann M, Weber DC. Optimizing clinical research and generating prospective high-quality data in particle therapy in Europe: Introducing the European Particle Therapy Network (EPTN). Radiother Oncol 2018;128:1-3. [PMID: 30049367 DOI: 10.1016/j.radonc.2018.06.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Dendale R, Thariat J, Doyen J, Balosso J, Stefan D, Bolle S, Feuvret L, Poortmans P, Hannoun-lévi J, Bondiau P, Micaud M, Alapetite C, Calugaru V, Habrand J, Mahé M. État des lieux de la protonthérapie en France en 2019. Cancer/Radiothérapie 2019;23:617-24. [DOI: 10.1016/j.canrad.2019.07.129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Baumann M, Ebert N, Kurth I, Bacchus C, Overgaard J. What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. Mol Oncol 2020;14:1577-85. [PMID: 32463984 DOI: 10.1002/1878-0261.12731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Weber DC, Grau C, Lim PS, Georg D, Lievens Y. Bringing Europe together in building clinical evidence for proton therapy - the EPTN-ESTRO-EORTC endeavor. Acta Oncol 2019;58:1340-2. [PMID: 31241391 DOI: 10.1080/0284186X.2019.1624820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
4 Weber DC, Bizzocchi N, Bolsi A, Jenkinson MD. Proton Therapy for Intracranial Meningioma for the Treatment of Primary/Recurrent Disease Including Re-Irradiation. Front Oncol 2020;10:558845. [PMID: 33381447 DOI: 10.3389/fonc.2020.558845] [Reference Citation Analysis]
5 Weber DC, Langendijk JA, Grau C, Thariat J. Proton therapy and the European Particle Therapy Network: The past, present and future. Cancer Radiother 2020;24:687-90. [PMID: 32753239 DOI: 10.1016/j.canrad.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Grau C, Durante M, Georg D, Langendijk JA, Weber DC. Particle therapy in Europe. Mol Oncol 2020;14:1492-9. [PMID: 32223048 DOI: 10.1002/1878-0261.12677] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
7 Tambas M, van der Laan HP, Steenbakkers RJHM, Doyen J, Timmermann B, Orlandi E, Hoyer M, Haustermans K, Georg P, Burnet NG, Gregoire V, Calugaru V, Troost EGC, Hoebers F, Calvo FA, Widder J, Eberle F, van Vulpen M, Maingon P, Skóra T, Weber DC, Bergfeldt K, Kubes J, Langendijk JA. Current practice in proton therapy delivery in adult cancer patients across Europe. Radiother Oncol 2021;167:7-13. [PMID: 34902370 DOI: 10.1016/j.radonc.2021.12.004] [Reference Citation Analysis]
8 Weber DC, Lim PS, Tran S, Walser M, Bolsi A, Kliebsch U, Beer J, Bachtiary B, Lomax T, Pica A. Proton therapy for brain tumours in the area of evidence-based medicine. Br J Radiol 2020;93:20190237. [PMID: 31067074 DOI: 10.1259/bjr.20190237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Witt Nyström P, Bratland Å, Minn H, Grau C. Ongoing and future clinical trials in particle therapy in the Nordic countries. Acta Oncol 2020;59:1145-50. [PMID: 32673134 DOI: 10.1080/0284186X.2020.1792548] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Tambas M, van der Laan HP, Rutgers W, van den Hoek JG, Oldehinkel E, Meijer TW, van der Schaaf A, Scandurra D, Free J, Both S, Steenbakkers RJ, Langendijk JA. Development of advanced preselection tools to reduce redundant plan comparisons in model-based selection of head and neck cancer patients for proton therapy. Radiotherapy and Oncology 2021;160:61-8. [DOI: 10.1016/j.radonc.2021.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Stokkevåg CH, Indelicato DJ, Herfarth K, Magelssen H, Evensen ME, Ugland M, Nordberg T, Nystad TA, Hægeland C, Alsaker MD, Ulven K, Dale JE, Engeseth GM, Boer CG, Toussaint L, Kornerup JS, Pettersen HES, Brydøy M, Brandal P, Muren LP. Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy. Acta Oncol 2019;58:1416-22. [PMID: 31364899 DOI: 10.1080/0284186X.2019.1643496] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
12 Sørensen BS, Pawelke J, Bauer J, Burnet NG, Dasu A, Høyer M, Karger CP, Krause M, Schwarz M, Underwood TSA, Wagenaar D, Whitfield GA, Lühr A. Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy? Radiother Oncol 2021;163:177-84. [PMID: 34480959 DOI: 10.1016/j.radonc.2021.08.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hwang EJ, Gorayski P, Le H, Hanna GG, Kenny L, Penniment M, Buck J, Thwaites D, Ahern V. Particle therapy tumour outcomes: An updated systematic review. J Med Imaging Radiat Oncol 2020;64:711-24. [PMID: 32270626 DOI: 10.1111/1754-9485.13021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ahern V. Selecting patients for proton beam therapy. J Med Radiat Sci 2021;68:2-3. [PMID: 33259660 DOI: 10.1002/jmrs.454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]